Clinical Trials

The New England Journal of Medicine has published the results from Novo Nordisk’s OASIS 4 Phase 3 trial, marking a major advance in obesity treatment with the investigational once-daily…
Read More...

Altasciences and VoxCell BioInnovation have announced a strategic collaboration aimed at transforming preclinical drug development by integrating advanced 3D bioprinted tissue models…
Read More...

Advarra announced the launch of the Council for Responsible Use of AI in Clinical Trials. The Council, which includes leaders from across the life sciences industry, will focus on…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational drug DYNE-101 for the treatment of…
Read More...

Capsida Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class…
Read More...

Novo Nordisk announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance…
Read More...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured…
Read More...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically…
Read More...

Coherus BioSciences, Inc. announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI…
Read More...

IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic…
Read More...

Ironwood Pharmaceuticals, Inc., a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced…
Read More...

Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the successful…
Read More...

Navidea Biopharmaceuticals, Inc. a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced disappointing results of an exploratory…
Read More...

Neumora Therapeutics, Inc. announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive…
Read More...

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic…
Read More...

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with…
Read More...

PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and…
Read More...

Johnson & Johnson announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2…
Read More...

Repare Therapeutics Inc. announced that, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40…
Read More...

Alcon announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the…
Read More...